INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2018. The put-call ratio across all filers is 0.27 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,671,000 | -18.4% | 35,907 | 0.0% | 0.01% | -29.4% |
| Q2 2022 | $2,049,000 | -6.7% | 35,907 | 0.0% | 0.02% | +13.3% |
| Q1 2022 | $2,197,000 | -64.3% | 35,907 | -69.5% | 0.02% | -61.5% |
| Q4 2021 | $6,156,000 | -66.0% | 117,617 | -75.8% | 0.04% | -68.3% |
| Q3 2021 | $18,097,000 | +38.8% | 485,466 | +52.0% | 0.12% | +38.2% |
| Q2 2021 | $13,041,000 | -6.4% | 319,487 | -29.9% | 0.09% | -23.3% |
| Q1 2021 | $13,930,000 | -3.9% | 456,022 | 0.0% | 0.12% | +0.9% |
| Q4 2020 | $14,502,000 | +31.4% | 456,022 | +6.1% | 0.12% | +10.6% |
| Q3 2020 | $11,033,000 | -24.6% | 430,000 | -24.6% | 0.10% | -32.5% |
| Q2 2020 | $14,633,000 | -51.1% | 570,000 | -36.2% | 0.15% | -53.6% |
| Q1 2020 | $29,951,000 | -2.2% | 893,000 | 0.0% | 0.33% | +1.2% |
| Q4 2019 | $30,639,000 | +346.8% | 893,000 | -2.7% | 0.33% | +260.4% |
| Q3 2019 | $6,857,000 | +2.4% | 918,000 | +77.2% | 0.09% | +9.6% |
| Q2 2019 | $6,694,000 | -16.5% | 518,000 | -21.3% | 0.08% | -19.4% |
| Q1 2019 | $8,015,000 | +10.3% | 658,000 | +3.1% | 0.10% | -8.0% |
| Q4 2018 | $7,267,000 | -38.9% | 638,000 | +16.4% | 0.11% | -29.1% |
| Q3 2018 | $11,892,000 | +184.0% | 548,000 | +131.2% | 0.16% | +139.4% |
| Q2 2018 | $4,188,000 | -8.7% | 237,000 | +8.7% | 0.07% | -15.4% |
| Q1 2018 | $4,589,000 | +13.2% | 218,000 | -22.1% | 0.08% | +11.4% |
| Q4 2017 | $4,054,000 | +45.1% | 280,000 | +58.2% | 0.07% | +42.9% |
| Q3 2017 | $2,793,000 | +45.1% | 177,000 | +14.2% | 0.05% | +36.1% |
| Q2 2017 | $1,925,000 | -38.3% | 155,000 | -19.3% | 0.04% | -40.0% |
| Q1 2017 | $3,120,000 | +76.8% | 192,000 | +64.1% | 0.06% | +46.3% |
| Q4 2016 | $1,765,000 | +5.3% | 117,000 | +6.4% | 0.04% | +2.5% |
| Q3 2016 | $1,676,000 | -81.1% | 110,000 | -52.0% | 0.04% | -82.7% |
| Q2 2016 | $8,890,000 | +139.9% | 229,000 | +70.9% | 0.23% | +148.4% |
| Q1 2016 | $3,705,000 | -49.4% | 134,000 | -1.6% | 0.09% | -52.6% |
| Q4 2015 | $7,326,000 | +57.4% | 136,200 | +17.2% | 0.20% | +71.9% |
| Q3 2015 | $4,653,000 | -15.3% | 116,200 | -32.4% | 0.11% | 0.0% |
| Q2 2015 | $5,495,000 | – | 172,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |